| Hollis-Eden Pharmaceuticals, Inc. reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone, or HE3235, for hormone-resistant prostate cancer, also called castrate-resistant prostate cancer, or CRPC. The interim results of the Phase I/II study, which is being conducted with participating member sites of the Prostate Cancer Clinical Trial Consortium, or PCCTC, demonstrated that 47% of subjects who were radiographically evaluable for response had stable disease. With the assessment of progression every 56 days, the median time to progression was 107 days. Forty-three percent of the biochemically evaluable subjects experienced a drop in PSA during treatment, with 33% equal to or greater than a 50% decline. The data was presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC. :theflyonthewall.com |
